Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BlossomHill TherapeuticsBLSM -0.06%8 Days Inventory is 0.00 as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100. Among 638 Biotechnology companies, BlossomHill Therapeutics ranks worse than 156739.66% on this metric.
The historical rank and industry rank for BlossomHill Therapeutics's Days Inventory or its related term are showing as below:
BLSM's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 179.22 * Ranked among companies with meaningful Days Inventory only.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BlossomHill Therapeutics (NAS:BLSM) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
BlossomHill Therapeutics's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
BlossomHill Therapeutics's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
BlossomHill Therapeutics Days Inventory Related Terms
BlossomHill Therapeutics Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics Days Inventory Chart
BlossomHill Therapeutics Annual Data
Trend
Dec24
Dec25
Days Inventory
0.00
0.00
BlossomHill Therapeutics Semi-Annual Data
Dec24
Dec25
Days Inventory
0.00
0.00
BLSM vs : Days Inventory Comparison
For the Biotechnology subindustry, BlossomHill Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BlossomHill Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BlossomHill Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where BlossomHill Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BlossomHill Therapeutics (BLSM) has a Days Inventory of 0.00 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BlossomHill Therapeutics and its competitors. According to the industry distribution chart, BlossomHill Therapeutics ranks #999999 out of 638 companies in the Biotechnology industry.
Is BlossomHill Therapeutics' Days Inventory too high?
BlossomHill Therapeutics' current Days Inventory is 0.00. Based on the distribution chart, BlossomHill Therapeutics ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Days Inventory compare to ?
According to the Biotechnology industry distribution chart, BlossomHill Therapeutics ranks #999999 out of 638 companies for Days Inventory. This places BlossomHill Therapeutics in the lower half of its industry. The industry median Days Inventory is 179.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 179.22, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on BlossomHill Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 179.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BlossomHill Therapeutics's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Days Inventory of 0.00. The current Days Inventory is 0.00. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Days Inventory is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score
Get the complete analysis for BLSM
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLSM has been successfully added to your 
